Other equities analysts have also issued research reports about the stock. Morgan Stanley set a $32.00 target price on shares of Bausch Health Companies and gave the company a buy rating in a report on Monday, December 17th. HC Wainwright upgraded shares of Bausch Health Companies from an average rating to a buy rating in a report on Friday, December 14th. Mizuho restated a buy rating and issued a $39.00 target price on shares of Bausch Health Companies in a report on Sunday, January 6th. UBS Group upgraded shares of Bausch Health Companies to a buy rating in a report on Wednesday, January 2nd. Finally, Zacks Investment Research upgraded shares of Bausch Health Companies from a hold rating to a buy rating and set a $28.00 target price on the stock in a report on Thursday, February 14th. Five equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and eleven have issued a buy rating to the stock. Bausch Health Companies currently has an average rating of Hold and an average price target of $27.36.
Shares of NYSE:BHC opened at $24.34 on Friday. The firm has a market cap of $8.56 billion, a PE ratio of 6.05, a price-to-earnings-growth ratio of 0.62 and a beta of 0.59. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 8.55. Bausch Health Companies has a 52 week low of $16.76 and a 52 week high of $28.45.
In related news, CEO Joseph C. Papa purchased 30,000 shares of the firm’s stock in a transaction on Thursday, February 28th. The stock was purchased at an average cost of $23.67 per share, with a total value of $710,100.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 11.87% of the company’s stock.
Large investors have recently bought and sold shares of the company. Vanguard Group Inc. bought a new stake in shares of Bausch Health Companies during the third quarter worth about $223,173,000. Morgan Stanley bought a new stake in shares of Bausch Health Companies during the third quarter worth about $57,631,000. Orbimed Advisors LLC increased its position in shares of Bausch Health Companies by 89.1% during the fourth quarter. Orbimed Advisors LLC now owns 3,600,300 shares of the company’s stock worth $66,498,000 after acquiring an additional 1,696,400 shares in the last quarter. Contravisory Investment Management Inc. bought a new stake in shares of Bausch Health Companies during the fourth quarter worth about $104,000. Finally, Financial Sense Advisors Inc. increased its position in shares of Bausch Health Companies by 7.7% during the fourth quarter. Financial Sense Advisors Inc. now owns 84,250 shares of the company’s stock worth $1,556,000 after acquiring an additional 6,050 shares in the last quarter. 54.67% of the stock is owned by institutional investors.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Featured Article: Correction
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.